A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Mariane Teodoro Fernandes(Faculdade de Medicina do ABC), Pedro Nazareth Aguiar(Sociedade Brasileira de Oncologia Clínica), Gilberto Lopes(University of Miami), Bárbara de Souza Gutierres(Universidade Paulista), Auro del Giglio(Faculdade de Medicina do ABC), Carmélia Maria Noia Barreto(Instituto de Medicina Avançada), Ana Cláudia Barbin Spinosa(Faculdade de Medicina do ABC), Jacob J. Adashek(South Texas Accelerated Research Therapeutics)
Drugs in Context
November 2, 2018
10.7573/dic.212555
Cited by 11

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
|Journal of Clinical Oncology|2022|334
The biology of cancer-related fatigue: a review of the literature
|Supportive Care in Cancer|2015|305